Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review

Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Nov 14, 2022: Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
Aug 11, 2022: Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
May 20, 2022: Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
May 10, 2022: Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Opiant Pharmaceuticals Inc - Key Facts
Opiant Pharmaceuticals Inc - Key Employees
Opiant Pharmaceuticals Inc - Key Employee Biographies
Opiant Pharmaceuticals Inc - Major Products and Services
Opiant Pharmaceuticals Inc - History
Opiant Pharmaceuticals Inc - Company Statement
Opiant Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis

Company Overview
Opiant Pharmaceuticals Inc - Business Description
Business Segment: Grant and Contract revenue
Performance
Business Segment: Royalty and Licensing revenue
Performance
Business Segment: Treatment Investment revenue
Performance
Opiant Pharmaceuticals Inc - Corporate Strategy
Opiant Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Opiant Pharmaceuticals Inc - Strengths
Opiant Pharmaceuticals Inc - Weaknesses
Opiant Pharmaceuticals Inc - Opportunities
Opiant Pharmaceuticals Inc - Threats
Opiant Pharmaceuticals Inc - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
Opiant Pharmaceuticals Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments

Nov 14, 2022: Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
Aug 11, 2022: Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
May 20, 2022: Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
May 10, 2022: Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Mar 15, 2022: Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Nov 11, 2021: Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 02, 2021: Opiant announces publication of manuscript treatment of overdose in the synthetic opioid era in peer-reviewed journal Pharmacology & Therapeutics
Aug 25, 2021: Opiant Pharmaceuticals to Participate in September Investor Conferences
Jul 12, 2021: Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
May 18, 2021: Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT

Section 6 - Appendix

Methodology
Ratio Definitions
About the Publisher
Contact the Publisher
Disclaimer

List of Tables

Opiant Pharmaceuticals Inc, Key Facts
Opiant Pharmaceuticals Inc, Key Employees
Opiant Pharmaceuticals Inc, Key Employee Biographies
Opiant Pharmaceuticals Inc, Major Products and Services
Opiant Pharmaceuticals Inc, History
Opiant Pharmaceuticals Inc, Subsidiaries
Opiant Pharmaceuticals Inc, Key Competitors
Opiant Pharmaceuticals Inc, Ratios based on current share price
Opiant Pharmaceuticals Inc, Annual Ratios
Opiant Pharmaceuticals Inc, Interim Ratios
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
Opiant Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Opiant Pharmaceuticals Inc, Performance Chart (2017 - 2021)
Opiant Pharmaceuticals Inc, Ratio Charts
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Camurus AB
BioDelivery Sciences International Inc
Orexo AB
Avalo Therapeutics Inc
Shire Pharmaceuticals International UC
Alkermes Plc
BioCorRx Inc
H. Lundbeck AS
Indivior Plc
Shire Pharmaceuticals International UC
Orexo AB
Indivior Plc
H. Lundbeck AS
Camurus AB
BioDelivery Sciences International Inc
BioCorRx Inc
Avalo Therapeutics Inc
Alkermes Plc

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€124EUR$125USD£103GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€248EUR$250USD£206GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€373EUR$375USD£310GBP